Press Releases

BRUSSELS, Belgium and WASHINGTON, D.C. – March 16, 2017 – The Alliance for Regenerative Medicine (ARM), the international advocacy organisation representing the cell and gene therapy and broader regenerative medicine sector, has taken note of the Letter from the Pharmaceutical Inspection Co-operation Scheme (PIC/S) to the European Commission stating their opposition, for public health reasons, to the publication of the Guidelines on Good Manufacturing Practice (GMP) for Advanced Therapy Medicinal Products (ATMPs) as a stand-alone document.

WASHINGTON, DC – March 13, 2017 – The Alliance for Regenerative Medicine (ARM) today issued the following statements on the Trump Administration’s nomination of Scott Gottlieb, M.D., as commissioner of the U.S. Food and Drug Administration (FDA).

WASHINGTON, D.C. – March 7, 2017 – The Alliance for Regenerative Medicine (ARM) today announced the release of its 2016 annual data report, offering an in-depth look at trends and metrics for the cell therapy, gene therapy, tissue engineering and broader global regenerative medicine sector.

BRUSSELS, Belgium and WASHINGTON, DC – February 16, 2017 – The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader regenerative medicine and advanced therapies sector, today announced it has published its position on Hospital Exemption (HE) in response to vastly different interpretations and implementations across the European Union of Article 3(7) of Directive 2001/83/EC within article 28 (2) of the Advanced Therapy Medicinal Products (ATMP) Regulation.

WASHINGTON, D.C., February 14, 2017 – The Alliance for Regenerative Medicine applauds the National Academies of Sciences, Engineering and Medicine for its very thorough and thoughtful report on the current scientific, technical, ethical, and policy issues relating to human genome editing.

WASHINGTON, D.C., February 2, 2017 – The Alliance for Regenerative Medicine (ARM) today announced its annual Cell & Gene Therapy Investor Day will take place April 27, 2017 in Boston, MA. The event is co-hosted by leading investment firm Piper Jaffray and held in partnership with Cowen & Co.

WASHINGTON, DC – January 30, 2017 – The Alliance for Regenerative Medicine (ARM) today announced it will host a free webinar titled “Understanding the 21st Century Cures Act for Cell & Gene Therapies.” During this one-hour live event, Michael Werner, Executive Director for ARM will be joined by Director Wilson W. Bryan, M.D., and Deputy Director Rachael F. Anatol, Ph.D., of the U.S.

WASHINGTON, DC – January 19, 2017 – The Alliance for Regenerative Medicine (ARM) today announced the formal launch of the international Standards Coordinating Body for regenerative medicines (SCB), a public-private partnership for coordinating, prioritizing and supporting standards that advances process, measurement and analytical techniques to support the global availability of products across the gene and gene-modified cell therapy, cell therapy, cell-based drug discovery, tissue engineering and biomaterials sectors.

WASHINGTON, D.C., December 15, 2016 – The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapies and broader regenerative medicine sector, announced its 2017 Cell & Gene Therapies State of the Industry briefing will take place January 9, 2017 in San Francisco, held in conjunction with Biotech Showcase™ 2017.

WASHINGTON, D.C., December 1, 2016 – The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cellular therapies and broader regenerative medicine sector, commends the U.S. House of Representatives’ bipartisan passage of the 21st Century Cures Act.

Pages